Recombinant Human IFNA1 protein (rFc Tag)(HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human IFNA1 protein (rFc Tag)(HPLC verified) (Eg2592)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg2592

---

Validation Data Gallery

• 

  Purity of Recombinant Human IFNA1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human IFNA1 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human IFNA1 protein Cys24-Glu189 (Accession# P01562) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 3439
• Accession: P01562
• PredictedSize: 45.4 kDa
• SDS-PAGE: 42-48 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in 0.5M arg, 30mM Tris, pH8.0. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IFNA1 (IF-alpha) is a member of the Type I IFN (1) family best known for their antiviral activity. It is a key cytokine regulating the activity of B cells, T-helper cells (Th cells), cDCs and natural killer cells (NK cells). IFNA1 induces B cell maturation into plasma cells and immunoglobulin production. IFNA1 plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). IFNA1 was the first cytokine to show clinical benefit in the treatment of certain types of cancer, including melanoma, chronic myelogenous leukemia, and renal cancer.

References:

1. Jeon K, Kim Y, et al. (2023) Front Immunol. 14:1101808. 
2. Jiang S, Sakamoto R, et al. (2019) Front Biosci (Landmark Ed).  24(4):790-797. 
3. Wang S, Chen SN, et al. (2021) Fish Shellfish Immunol. 117:70-81.